Chemistry Reference
In-Depth Information
[38] Corey WT, Lima MF, Villalta F.
Trypanosoma cruzi
uses a 45-KDa mucin for adhesion to mammalian cells.
Biochem Biophys Res Commun. 2002; 290: 29-34.
[39] Pereira VL, Serrano A, Almeida IC
et al.
Mucin-like molecules form a negatively charged coat that protects
Trypanosoma cruzi
trypomastigotes from killing by human anti-α-galactosyl antibodies.
Journal of Cell
Science 2000; 113(7): 1299-1307.
[40] Amaya MF, Watts AG, Damager I
et al.
Structural insights into the catalytic mechanism of
Trypanosoma
cruzi
trans
-sialidase. Structure 2004; 12: 775-784.
[41] Neres J, Bryce RA, Douglas KT. Rational drug design in parasitology:
trans
-sialidase as a case study for
Chagas' disease.
Drug Discovery Today 2008; 13(3): 110-117.
[42] Paris G, Ratier L, Amaya MF
et al.
A sialidase mutant displaying
trans
-sialidase activity. J. Mol. Biol
2005;
345: 923-934.
[43] Watts AG, Damager I, Amaya ML
et al. Trypanosoma cruzi trans
-sialidase operates through a covalent sialyl-
enzyme intermediate: tyrosine is the catalytic nucleophile
.
J. Am. Chem. Soc. 2003; 25; 125(25): 7532-7533.
[44] Buchini S, Buschiazzo A, Withers SG. A new generation of specific
Trypanosoma cruzi trans
-sialidase
inhibitors. Angew. Chem. Int. Ed. 2008 Feb 25; 47(14): 2700-2703.
[45] Streicher H, Busse H. Building a successful structural motif into sialylmimetics-cyclohexenephosphonate
monoesters as pseudo-sialosides with promising inhibitory properties. Bioorg. Med. Chem. 2006 Feb 15;
14(4): 1047-1057.
[46] Ferrero-Garcia MA, Sanches DO, Frasch AC
et al.
The effect of pyridoxal 5'-phosphate and related
compounds on
Trypanosoma cruzi
trans
-sialidase. J. An. Asoc. Quim. Arg 1993; 81: 127-132.
[47] Neres J, Bonnet P, Edwards PN,
et al.
Benzoic acid and pyridine derivatives as inhibitors of
Trypanosoma
cruzi
trans
-sialidase. Bioorg. Med. Chem. 2007 Mar 1; 15(5): 2106-2119.
[48] Agusti R, Paris G, Ratier L
et al.
Lactose derivatives are inhibitors of
Trypanosoma
cruzi
trans
-sialidase
activity toward conventional substrates
in vitro
and in vivo. Glycobiology 2004; 14: 659-670.
[49] Agusti R, Giorgi ME, Mendoza VM
et al.
Comparative rates of sialylation by recombinant
trans
-sialidase and
inhibitor properties of synthetic oligosaccharides from
Trypanosoma cruzi
mucins-containing galactofuranose
and galactopyranose. Bioorg. Med. Chem. 2007; 1; 15(7): 2611-2616.
[50] Busse H, Hakoda M, Stanley M
et al.
Galactose-phosphonates as mimetics of the sialyltransfer by
trypanosomal sialidases. J. Carbohydr. Chem. 2007; 26(3): 159-194.
[51] RobinsonJA.Horizons in chemical immunology: approaches to synthetic vaccine design. Chimia 2007, 61(3):
84-92.
[52] Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol
2005, 83(4): 418-428.
[53] Cunto-Amesty G, Monzavi-Karbassi B, Luo P
et al.
Strategies in cancer vaccines development. Int J Parasitol
2003, 33(5-6): 597-613.
[54] Keding SJ, Endo A, Danishefsky SJ. Synthesis of non-natural glycosylamino acids containing tumor-
associated carbohydrate antigens. Tetrahedron 2003, 59(35): 7023-7031.
[55] Vichier-Guerre S, Lo-Man R, Huteau V
et al.
Synthesis and immunological evaluation of an antitumor
neoglycopeptide vaccine bearing a novel homoserine Tn antigen. Bioorg Med Chem Lett 2004, 14(13): 3567-
3570.
[56] Galonic DP, Gin, DY. Chemical glycosylation in the synthesis of glycoconjugate antitumor vaccines. Nature
2007, 446(7139): 1000-1007.
[57] Brocke C, Kunz H. Synthesis of tumor-associated glycopeptide antigens. Bioorg Med Chem 2002, 10(10):
3085-3112.
[58] Meinjohanns E, Meldal M, Jensen T
et al.
Versatile solid-phase thiolytic reduction of azido and N-Dts groups
in the synthesis of hemoglobin (67-76) O-glycopeptides and photoaffinity labeled analogs to study glycan T-
cell specificity. J. Chem. Soc., Perkin Trans. 1 1997, (6): 871-884.
[59] Slovin SF, Ragupathi G, Musselli C
et al.
Fully synthetic carbohydrate-based vaccines in biochemically
relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-O-serine/threonine conjugate
vaccine. J Clin Oncol 2003, 21(23): 4292-4298.